Cyclin-dependent kinase inhibition by flavoalkaloids

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 632-649

  Jain, S K ^a   Bharate, S B ^a   Vishwakarma, R A ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Cancer; Cyclin dependent kinase; Dysoxylum binectariferum; Flavoalkaloid; Flavopiridol; P 276 00; Rohitukine

Indexed keywords

ALKALOID; APIGENIN; BAICALEIN; BAICALIN; BORTEZOMIB; CHRYSIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEPSIPEPTIDE; DOCETAXEL; FISETIN; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GENISTEIN; IRINOTECAN; KAEMPFEROL; LENALIDOMIDE; LUTEOLIN; MITOXANTRONE; OXALIPLATIN; P 276 00; QUERCETIN; RITUXIMAB; ROHITUKINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GERM CELL TUMOR; HUMAN; HYPOTENSION; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMACYTOMA; REVIEW; SIDE EFFECT; SMALL CELL CARCINOMA; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; SWEATING; XEROSTOMIA;

EID: 84861721783     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800626683     Document Type: Review

References (113)

1. Martens, S.; Mithofer, A. Flavones and flavone synthases. Phytochemistry 2005, 66, 2399-407.
2. Mizutani, M.; Tanaka, Y.; Kusumi, T.; Ayabe, S.; Akashi, T. Flavone synthases, methods of using flavone synthases, and plants expressing flavone synthases. U. S Patent 7465569 (International Flower Developments Proprietary Limited, Australia) 2008.
3. Pichersky, E.; Gang, D.R. Genetics and biochemistry of secondary metabolites in plants: an evolutionary perspective. Trends Plant Sci. 2000, 5, 439-45.
4. Spaink, H.P. The molecular basis of infection and nodulation by Rhizobia: The ins and outs of sympathogenesis. Annu. Rev. Phytopathol. 1995, 33, 345-68.
5. Harborne, J.B.; Williams, C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55, 481-504.
6. Pietta, P.; Minoggio, M.; Bramati, L.; Rahman, A.-U. Plant polyphenols: Structure, occurrence and bioactivity. In Studies in Natural Products Chemistry, Elsevier: 2003; Vol. 28, Part 9, pp 257-312.
7. Verma, A.K.; Pratap, R. The biological potential of flavones. Nat. Prod. Rep. 2010, 27, 1571-93.
8. Kosmider, B.; Osiecka, R. Flavonoid compounds: A review of anticancer properties and interactions with cis-Diamminedichloroplatinum(II). Drug Dev. Res. 2004, 63, 200-11.
9. Ren, W.; Qiao, Z.; Wang, H.; Lei Zhu, L.Z. Flavonoids: Promising anticancer agents. Med. Res. Rev. 2003, 23, 519-34.
10. Teillet, F.; Boumendjel, A.; Boutonnat, J.; Ronot, X. Flavonoids as RTK inhibitors and potential anticancer agents. Med. Res. Rev. 2008, 28, 715-45.
11. Wang, H.K. The therapeutic potential of flavonoids. Expert Opin. Investig. Drugs 2000, 9, 2103-19.
12. Wang, H.K.; Xia, Y.; Yang, Z.Y.; Natschke, S.L.; Lee, K.H. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv. Exp. Med. Biol. 1998, 439, 191-225.
13. Boumendjel, A.; Pietro, A.D.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with highaffinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev. 2002, 22, 512-29.
14. Roger, C.R. The nutritional incidence of flavonoids: Some physiological and metabolic considerations. Experientia 1988, 44, 725-33.
15. Cotelle, N.; Bernier, J.L.; Henichart, J.P.; Catteau, J.P.; Gaydou, E.; Wallet, J.C. Scavenger and antioxidant properties of ten synthetic flavones. Free Radic. Biol. Med. 1992, 13, 211-9.
16. DiCarlo, G.; Mascolo, N.; Izzo, A.A.; Capasso, F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci. 1999, 65, 337-53.
17. Kuntz, S.; Wenzel, U.; Daniel, H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur. J. Nutr. 1999, 38, 133-42.
18. Choi, S.U.; Ryu, S.Y.; Yoon, S.K.; Jung, N.P.; Park, S.H.; Kim, K.H.; Choi, E.J.; Lee, C.O. Effects of flavonoids on the growth and cell cycle of cancer cells. Anticancer Res. 1999, 19, 5229-33.
19. Kaulich, M.; Streicher, F.; Mayer, R.; Muller, I.; Muller, C.E. Flavonoids-Novel lead compounds for the development of P2Y2 receptor antagonists. Drug Dev. Res. 2003, 59, 72-81.
20. Campbell, D.R.; Kurzer, M.S. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid Biochem. Mol. Biol. 1993, 46, 381-8.
21. Ibrahim, A.R.; Abul-Hajj, Y.J. Aromatase inhibition by flavonoids. J. Steroid Biochem. Mol. Biol. 1990, 37, 257-60.
22. Yamashita, Y.; Kawada, S.; Nakano, H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem. Pharmacol. 1990, 39, 737-44.
23. Ferriola, P.C.; Cody, V.; Middleton, E. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol. 1989, 38, 1617-24.
24. Lin, C.W.; Hou, W.C.; Shen, S.C.; Juan, S.H.; Ko, C.H.; Wang, L.M.; Chen, Y.C. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 2008, 29, 1807-15.
25. Choi, J.A.; Kim, J.Y.; Lee, J.Y.; Kang, C.M.; Kwon, H.J.; Yoo, Y.D.; Kim, T.W.; Lee, Y.S.; Lee, S.J. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol. 2001, 19, 837-44.
26. Zi, X.; Feyes, D.K.; Agarwal, R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an Increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclindependent kinases and associated cyclins. Clin. Cancer Res. 1998, 4, 1055-64.
27. Cushman, M.; Zhu, H.; Geahlen, R.L.; Kraker, A.J. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J. Med. Chem. 1994, 37, 3353-62.
28. Senderowicz, A.M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001, 15, 1-9.
29. Neant, I.; Guerrier, P. 6-Dimethylaminopurine blocks starsh oocyte maturation by inhibiting a relevant protein kinase activity. Exp. Cell Res. 1988, 176, 68-79.
30. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J.J.; Donella-Deana, A.; Pinna, L.; Letham, D.S.; Kato, J.Y.; DeÂtivaud, L.; Leclerc, J.; Meijer, L. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 1994, 224, 771-9.
31. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.P.; Blow, J.J.; Inagaki, N.; Inagaki, M.; Delcros, J.G.; Moulinoux, J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527-36.
32. Gray, N.; Detivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-75.
33. Gray, N.S.; Wodicka, L.; Thunnissen, A.M.; Norman, T.C.; Kwon, S.; Espinoza, F.H.; Morgan, D.O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.H.; Lockhart, D.J.; Schultz, P.G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-8.
34. Lu, H.; Chang, D.J.; Baratte, B.; Meijer, L.; Schulze-Gahmen, U. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor fisetin. J. Med. Chem. 2005, 48, 737-43.
35. Zhang, S.; Ma, J.; Bao, Y.; Yang, P.; Zou, L.; Li, K.; Sun, X. Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: synthesis, SAR analysis, and biological activity. Bioorg. Med. Chem. 2008, 16, 7128-33.
36. Lee, H.Z.; Leung, H.W.; Lai, M.Y.; Wu, C.H. Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res. 2005, 25, 959-64.
37. Vijayababu, M.R.; Kanagaraj, P.; Arunkumar, A.; Ilangovan, R.; Aruldhas, M.M.; Arunakaran, J. Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J. Cancer Res. Clin. Oncol. 2005, 131, 765-71.
38. Khadem, S.; Marles, R.J. Chromone and flavonoid alkaloids: Occurrence and bioactivity. Molecules 2012, 17, 191-206.
39. Harmon, A.D.; Weiss, U.; Silverton, J.V. The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Meliaceae). Tetrahedron Lett. 1979, 8, 721-4.
40. Naik, R.G.; Kattige, S.L.; Bhat, S.V.; Alreja, B.; de Souza, N.J.; Rupp, R.H. An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 1988, 44, 2081-6.
41. Wang, L.M.; Ren, D.M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini-Rev. Med. Chem. 2010, 10, 1058-70.
42. Kattige, S.L.; Naik, R.G.; Lakdawalla, A.D.; Alihussein, N.D.; Rupp, R.H.; Souza, N.J. 4H-Benzopyran-4-one Compounds Which Have Antiinflammatory or Immunomodulating Action. U.S. Patent 4,900,727, Feb 13, 1990.
43. Tabaka, A.C.; Murthi, K.K.; Pal, K.; Teleha, C.A. Application of modified flavone closure for the preparation of racemic L86-8275. Org. Proc. Res. Dev. 1999, 3, 256-9.
44. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chao, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; Humphreys, W.G.; Wautlet, B.S.; Mulheron, J.G.; Webster, K.R. Thio-and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. 2000, 43, 4126-34.
45. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P. Structurebased design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. 2002, 45, 1741-7.
46. Sivakumar, M.; Shukla, M.; Jadhav, P.K.; Borhade, A. An enantioselective synthesis of pyrrolidine-substituted flavones. WO2008007169 (Piramal Life Science Ltd. India), 2008.
47. Ali, A.; Ghosh, A.; Nathans, R.S.; Sharova, N.; O'Brien, S.; Cao, H.; Stevenson, M.; Rana, T.M. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. ChemBioChem 2009, 10, 2072-80.
48. Murthi, K.K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M.D.; Worland, P.J.; Mansuri, M.M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-41.
49. Ahn, Y.M.; Vogeti, L.; Liu, C.J.; Santhapuram, H.K.; White, J.M.; Vasandani, V.; Mitscher, L.A.; Lushington, G.H.; Hanson, P.R.; Powell, D.R.; Himes, R.H.; Roby, K.F.; Ye, Q.; Georg, G.I. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorg. Med. Chem. 2007, 15, 702-13.
50. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor P276-00. Mol. Cancer Ther. 2007, 6, 918-25.
51. Raje, N.; Hideshima, T.; Mukherjee, S.; Raab, M.; Vallet, S.; Chhetri, S.; Cirstea, D.; Pozzi, S.; Mitsiades, C.; Rooney, M.; Kiziltepe, T.; Podar, K.; Okawa, Y.; Ikeda, H.; Carrasco, R.; Richardson, P.G.; Chauhan, D.; Munshi, N.C.; Sharma, S.; Parikh, H.; Chabner, B.; Scadden, D.; Anderson, K.C. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009, 23, 961-70.
52. Senderowicz, A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs 1999, 17, 313-20.
53. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 1992, 84, 1736-40.
54. Losiewicz, M.D.; Carlson, B.A.; Kaur, G.; Sausville, E.A.; Worland, P.J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 1994, 201, 589-95.
55. Sedlacek, H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 2001, 38, 139-70.
56. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-60.
57. Carlson, B.A.; Dubay, M.M.; Sausville, E.A.; Brizuela, L.; Worland, P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996, 56, 2973-8.
58. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 2000, 9, 2903-11.
59. Worland, P.J.; Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Sartor, O.; Sausville, E.A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol. 1993, 46, 1831-40.
60. Kim, D.M.; Koo, S.Y.; Jeon, K.; Kim, M.H.; Lee, J.; Hong, C.Y.; Jeong, S. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-a or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res. 2003, 63, 621-6.
61. Cartee, L.; Maggio, S.C.; Smith, R.; Sankala, H.M.; Dent, P.; Gran, S. Protein kinase C-dependent activation of the Tumor necrosis factor receptor-mediated extrinsic cell Death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol. Cancer Ther. 2003, 2, 83-93.
62. Wu, K.; Wang, C.; D'Amico, M.; Lee, R.J.; Albanese, C.; Pestell, R.G.; Mani, S. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol. Cancer Ther. 2002, 1, 695-706.
63. Nahta, R.; Iglehart, J.D.; Kempkes, B.; Schmidt, E.V. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res. 2002, 62, 2267-71.
64. Arguello, F.; Alexander, M.; Sterry, J.A.; Tudor, G.; Smith, E.M.; Kalavar, N.T.; Greene, J.F.; Koss, W.; Morgan, C.D.; Stinson, S.F.; Siford, T.J.; Alvord, W.G.; Klabansky, R.L.; Sausville, E.A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 1998, 91, 2482-90.
65. Gojo, I.; Zhang, B.; Fenton, R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down regulation of Mcl-1. Clin. Cancer Res. 2002, 8, 3527-38.
66. Wittmann, S.; Bali, P.; Donapaty, S.; Nimmanapalli, R.; Guo, F.; Yamaguchi, H.; Huang, M.; Jove, R.; Wang, H.G.; Bhalla, K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003, 63, 93-9.
67. Carlson, B.; Lahusen, T.; Singh, S.; Loaiza-Perez, A.; Worland, P.J.; Pestell, R.; Chris Albanese; Sausville, E.A.; Senderowicz, A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999, 59, 4634-41.
68. Rapella, A.; Negrioli, A.; Melillo, G.; Pastorino, S.; Varesio, L.; Bosco, M.C. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int. J. Cancer 2002, 99, 658-64.
69. Melillo, G.; Sausville, E.A.; Cloud, K.; Lahusen, T.; Varesio, L.; Senderowicz, A.M. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999, 59, 5433-7.
70. Takada, Y.; Aggarwal, B.B. Flavopiridol inhibits NF-kB activation induced by various carcinogens and inflammatory agents through inhibition of IkBa kinase and p65 phosphorylation. J. Biol. Chem. 2004, 279, 4750-9.
71. Michalides, R.; van Veelen, N.; Hart, A.; Loftus, B.; Wientjens, E.; Balm, A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995, 55, 975-8.
72. Brusselbach, S.; Nettelbeck, D.M.; Sedlacek, H.H.; Muller, R. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int. J. Cancer 1998, 77, 146-52.
73. Kerr, J.S.; Wexler, R.S.; Mousa, S.A.; Robinson, C.S.; Wexler, E.J.; Mohamed, S.; Voss, M.E.; Devenny, J.J.; Czerniak, P.M.; Gudzelak, A.; Slee, A.M. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res. 1999, 19, 959-68.
74. Sedlacek, H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A.; Senderowicz, A.; Sausville, E. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 1996, 9, 1143-68.
75. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 2000, 9, 2903-11.
76. Drees, M.; Dengler, W.A.; Roth, T.; Labonte, H.; Mayo, J.; Malspeis, L.; Grever, M.; Sausville, E.A.; Fiebig, H.H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. 1997, 3, 273-9.
77. Byrd, J.C.; Shinn, C.; Waselenko, J.K.; Fuchs, E.J.; Lehman, T.A.; Nguyen, P.L. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998, 92, 3804-16.
78. Thomas, J.P.; Tutsch, K.D.; Cleary, J.F.; Bailey, H.H.; Arzoomanian, R.; Alberti, D. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother. Pharmacol. 2002, 50, 465-72.
79. Parker, B.W.; Kaur, G.; Nieves-Neira, W.; Taimi, M.; Kohlhagen, G.; Shimizu, T.; Losiewicz, M.D.; Pommier, Y.; Sausville, E.A.; Senderowicz, A.M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998, 91, 458-65.
80. Arguello, F.; Alexander, M.; Sterry, J.A.; Tudor, G.; Smith, E.M.; Kalavar, N.T.; Greene, J.F., Jr.; Koss, W.; Morgan, C.D.; Stinson, S.F.; Siford, T.J.; Alvord, W.G.; Klabansky, R.L.; Sausville, E.A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 1998, 91, 2482-90.
81. Bradbury, R.H. Kinase inhibitors: Approved drugs and clinical candidates. In Burger's medicinal chemistry, drug discovery, and development, 7th ed.; Abraham, D.J.; Rotella, D.P., Eds. John Wiley & Sons, Inc.: 2010.
82. Diaz-Padilla, I.; Siu, L.L.; Duran, I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest. New Drugs 2009, 27, 586-94.
83. Burdette-Radoux, S.; Tozer, R.G.; Lohmann, R.C.; Quirt, I.; Ernst, D.S.; Walsh, W. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor in untreated metastatic malignant melanoma. Invest. New Drugs 2004, 22, 315-22.
84. Liu, G.; Gandara, D.R.; Lara, P.; Raghavan, D.; Doroshow, J.H.; Twardowski, P. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin. Cancer Res. 2004, 10, 924-8.
85. Stadler, W.M.; Vogelzang, N.J.; Amato, R.; Sosman, J.; Taber, D.; Liebowitz, D.; Vokes, E.E. Flavopiridol, a novel cyclin-dependent kinase inhibitor in metastatic renal cancer: A University of Chicago Phase II consortium study. J. Clin. Oncol. 2000, 18, 371-5.
86. Brown, J.R. Chronic lymphocytic leukemia: a niche for flavopiridol? Clin. Cancer Res. 2005, 11, 3971-3.
87. Christian, B.A.; Grever, M.R.; Byrd, J.C.; Lin, T.S. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol. 2007, 19, 573-8.
88. Misra, R.N. Clinical progress of selective cyclin dependent kinase (CDK) inhibitors. Drugs Future 2006, 31, 43-52.
89. Blagosklonny, M.V. Flavopiridol, an inhibitor of transcription. Implications, problems and solutions. Cell Cycle 2004, 3, 1537-42.
90. Getman, C.R.; Bible, K.C. Molecular targets of flavopiridol, a promising new antineoplastic agent. Recent Res. Dev. Cancer 2004, 6, 37-56.
91. Phelps, M.A.; Lin, T.S.; Johnson, A.J.; Hurh, E.; Rozewski, D.M.; Farley, K.L.; Wu, D.; Blum, K.A.; Fischer, B.; Mitchell, S.M.; Moran, M.E.; Brooker-McEldowney, M.; Heerema, N.A.; Jarjoura, D.; Schaaf, L.J.; Byrd, J.C.; Grever, M.R.; Dalton, J.T. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113, 2637-45.
92. Dispenzieri, A.; Gertz, M.A.; Lacy, M.Q.; Geyer, S.M.; Fitch, T.R.; Fenton, R.G.; Fonseca, R.; Isham, C.R.; Ziesmer, S.C.; Erlichman, C.; Bible, K.C. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006, 91, 390-3.
93. Byrd, J.C.; Lin, T.S.; Dalton, J.T.; Wu, D.; Phelps, M.A.; Fischer, B.; Moran, M.; Blum, K.A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L.J.; Johnson, A.J.; Lucas, D.M.; Heerema, N.A.; Lozanski, G.; Young, D.C.; Suarez, J.-R.; Colevas, A.D.; Grever, M.R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109, 399-404.
94. Motwani, M.; Jung, C.; Sirotnak, F.M.; She, Y.; Shah, M.A.; Gonen, M.; Schwartz, G.K. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. 2001, 7, 4209-19.
95. Shah, M.A.; Schwartz, G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7, 2168-81.
96. Bible, K.C.; Kaufmann, S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res. 1997, 57, 3375-80.
97. Cartee, L.; Wang, Z.; Decker, R.H.; Chellappan, S.P.; Fusaro, G.; Hirsch, K.G.; Sankala, H.M.; Dent, P.; Grant, S. The cyclindependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res. 2001, 61, 2583-91.
98. Motwani, M.; Rizzo, C.; Sirotnak, F.; She, Y.; Schwartz, G.K. Flavopiridol enhances the effects of docetaxel in vitro and in vivo in human gastric cancer cells. Mol. Cancer Ther. 2003, 2, 549-55.
99. Motwani, M.; Delohery, T.M.; Schwartz, G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. 1999, 5, 1876-83.
100. El-Rayes, B.F.; Gadgeel, S.; Parchment, R.; Lorusso, P.; Philip, P.A. A phase I study of flavopiridol and docetaxel. Invest. New Drugs 2006, 24, 305-10.
101. Shah, M.A.; Kortmansky, J.; Motwani, M.; Drobnjak, M.; Gonen, M.; Yi, S. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res. 2005, 11, 3836-45.
102. Fornier, M.N.; Rathkopf, D.; Shah, M.A.; Patil, S.; O'Reilly, E.; Tse, A.N. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin. Cancer Res. 2007, 13, 5841-6.
103. Carvajal, R.D.; Shah, M.A.; Tse, R. A phase II study of docetaxel followed by flavopiridol in advanced, gemcitabine-refractory pancreatic cancer. Proc. Am. Soc. Clin Oncol. abstr. 2008, 15558.
104. George, S.; Kasimis, B.S.; Cogswell, J.; Schwarzenberger, P.; Shapiro, G.I.; Fidias, P. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with nonsmall-cell lung cancer. Clin. Lung Cancer 2008, 9, 160-5.
105. Dickson, M.A.; Shah, M.A.; Rathkopf, D.; Tse, A.; Carvajal, R.D.; Wu, N.; Lefkowitz, R.A.; Gonen, M.; Cane, L.M.; Dials, H.J.; Schwartz, G.K. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother. Pharmacol. 2010, 66, 1113-21.
106. Holkova, B.; Perkins, E.B.; Ramakrishnan, V.; Tombes, M.B.; Shrader, E.; Talreja, N.; Wellons, M.D.; Hogan, K.T.; Roodman, G.D.; Coppola, D.; Kang, L.; Dawson, J.; Stuart, R.K.; Peer, C.; Figg, W.D.; Kolla, S.; Doyle, A.; Wright, J.; Sullivan, D.M.; Roberts, J.D.; Grant, S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin. Cancer Res. 2011, 17, 3388-97.
107. Hirte, H.W.; Raghunadharao, D.; Baetz, T.; Hotte, S.; Rajappa, S.; Iacobucci, A.; Sharma, S.; Parikh, H.; Kulkarni, S.; Patil, S.; Gaston, S. A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. J. Clin. Oncol. (Abstract: ASCO Annual Meeting Proceedings) 2007, 25, 14117.
108. Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.H.; Sharma, S. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol. Cancer Ther. 2007, 6, 926-34.
109. Giridharan, P.; Chakrabarti, D.; Khanna, A.; Ved, U.; Almeida, A.; Sharma, S.; Padigaru, M.; Balakrishnan, A. Novel syngergistic combination of gemcitabine with P-276-00 or PI446A in treatment of cancer. US2010/0152129 (Piramal Life Science Ltd. India), 2010.
110. Rathos, M.; Joshi, K.; Khanwalkar, H.; Sharma, S. A synergistic pharmaceutical combination for the treatment of cancer. WO2008/139271 (Piramal Life Sciences Ltd. India), 2008.
111. De Azevedo, W.F., Jr.; Mueller-Dieckmann, H.J.; Schulze-Gahmen, U.; Worland, P.J.; Sausville, E.; Kim, S.H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA 1996, 93, 2735-40.
112. Huwe, A.; Mazitschek, R.; Giannis, A. Small molecules as inhibitors of cyclin-dependent kinases. Angew. Chem. Int. Ed. 2003, 42, 2122-38.
113. Galons, H.; Oumata, N.; Meijer, L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin. Ther. Patents 2010, 20, 377-404.